Table 1.
Baseline characteristics of the patients
| Control group | Continuous monitoring group | |
|---|---|---|
| N | 58 | 62 |
| Female sex, number (%) | 19 (33) | 26 (42) |
| Age (years)* | 26.0 ± 14.6 | 25.7 ± 14.1 |
| Pediatric, number (%) | 26 (45) | 27 (44) |
| BMI (kg/m2)* | 22.0 ± 3.8 | 22.4 ± 3.8 |
| Duration of diabetes (years)* | 11.4 ± 11.4 | 11.6 ± 11.3 |
| Insulin administration, number (%) | ||
| Pump | 34 (59) | 47 (76) |
| MDI | 24 (41) | 15 (24) |
| Glycated hemoglobin at screening (%)* | 6.90 ± 0.47 | 6.83 ± 0.44 |
| Glycated hemoglobin at baseline (%)* | 6.91 ± 0.67 | 6.92 ± 0.56 |
| Record of severe hypoglycemia in last year, number (%) | 7 (12) | 5 (8) |
| Diagnosed with hypoglycemia unawareness, number (%) | 4 (7) | 6 (10) |
| Daily insulin dose (units/kg)* | 0.67 ± 0.32 | 0.66 ± 0.25 |
| Education, number (%) | ||
| Pediatric patient still in education | 26 (45) | 29 (47) |
| Completed education by age 18 | 3 (5) | 6 (10) |
| Completed further education | 29 (50) | 27 (44) |
| Prior use of continuous glucose monitor, number (%) | 18 (31) | 21 (34) |
| Mean blood glucose in 1-month run-in period (mg/dL)* | 148 ± 28 | 147 ± 23 |
| SMBG measurements per day in 1-month run-in period* | 5.1 ± 2.5 | 5.3 ± 2.2 |
Differences between the control and the continuous monitoring group were not statistically significant. MDI, multiple daily injection.
*Means ± SD.